Lantheus Holdings, Inc. (LNTH)
| Market Cap | 6.58B +76.4% |
| Revenue (ttm) | 1.56B +2.3% |
| Net Income | 275.31M +1.6% |
| EPS | 4.15 +10.1% |
| Shares Out | 65.27M |
| PE Ratio | 24.29 |
| Forward PE | 17.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,380,139 |
| Open | 101.43 |
| Previous Close | 100.96 |
| Day's Range | 100.74 - 101.43 |
| 52-Week Range | 49.67 - 111.86 |
| Beta | -0.03 |
| Analysts | Hold |
| Price Target | 107.16 (+6.23%) |
| Earnings Date | Aug 6, 2026 |
About LNTH
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked o... [Read more]
Financial Performance
In 2025, Lantheus Holdings's revenue was $1.54 billion, an increase of 0.50% compared to the previous year's $1.53 billion. Earnings were $233.56 million, a decrease of -25.25%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for LNTH stock is "Hold." The 12-month stock price target is $107.16, which is an increase of 6.23% from the latest price.
News
Lantheus Holdings Proxy statement: Proxy filing
Lantheus Holdings filed a proxy statement on August 26, 2026, providing details for shareholder voting and corporate governance matters.
Lantheus downgraded to Neutral from Buy at B. Riley
B. Riley downgraded Lantheus (LNTH) to Neutral from Buy with a price target of $105.40, down from $129, after Curium agreed to acquire all of the outstanding shares of Lantheus…
Lantheus announces FDA approval of Tauklarify
Lantheus (LNTH) announced FDA approval of Tauklarify, also referred to as MK-6240, a radiodiagnostic agent indicated for positron emission tomography of the brain in adults with cognitive impairment w...
US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment
The U.S. Food and Drug Administration has approved a radioactive agent from Lantheus Holdings for use in brain scans to help assess patients for Alzheimer's disease, the company said on Friday.
Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer's Disease
BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians...
Lantheus Holdings Proxy statement: Proxy filing
Lantheus Holdings filed a proxy statement on August 13, 2026, providing details for shareholder voting and corporate governance matters.
Lantheus Holdings Earnings release: Q2 2026
Lantheus Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Lantheus Holdings Quarterly report: Q2 2026
Lantheus Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
Lantheus reports Q2 adjusted EPS $1.55, consensus $1.30
Reports Q2 revenue $388.2M, consensus $363.23M. The company said, “In addition, and as previously announced, Lantheus (LNTH) entered into a definitive agreement on August 3, 2026 to merge with Curium…
Lantheus Reports Second Quarter 2026 Financial Results
Worldwide revenue of $388.2 million in the second quarter of 2026 GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 Adjusted fully diluted earnings per sh...
Lantheus downgraded to Market Perform from Outperform at CJS Securities
CJS Securities downgraded Lantheus (LNTH) to Market Perform from Outperform after Curium agreed to acquire Lantheus for $102.50 per share in cash at closing plus contingent value rights worth up…
Lantheus Holdings Proxy statement: Proxy filing
Lantheus Holdings filed a proxy statement on August 4, 2026, providing details for shareholder voting and corporate governance matters.
Lantheus Holdings Proxy statement: Proxy filing
Lantheus Holdings filed a proxy statement on August 4, 2026, providing details for shareholder voting and corporate governance matters.
Lantheus downgraded to Hold from Buy at Truist
Truist downgraded Lantheus (LNTH) to Hold from Buy with a price target of $102.50, down from $125, after Curium agreed to acquire all of the outstanding shares of Lantheus for…
Lantheus downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Lantheus (LNTH) to Hold from Buy with a price target of $102.50, down from $110, after Curium agreed to acquire all of the outstanding shares of Lantheus…
Lantheus downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Lantheus (LNTH) to Market Perform from Outperform with a $102.50 price target after Curium agreed to acquire all of the outstanding shares of Lantheus for $102.50 per share…
Lantheus Holdings to Be Acquired for Initial $6.7 Billion
Curium said it would pay $102.50 a share in cash for Lantheus, a 2.9% premium to Friday's closing price of $99.64 and 8.5% above Lantheus's closing price of $94.47 on May 21, before Bloomberg reported...
Lantheus downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Lantheus (LNTH) to Market Perform from Outperform. The firm, which believes the Curium merger “represents an excellent outcome for Lantheus shareholders,” believes it is unlik...
Lantheus Holdings Proxy statement: Proxy filing
Lantheus Holdings filed a proxy statement on August 3, 2026, providing details for shareholder voting and corporate governance matters.
Lantheus Holdings Proxy statement: Proxy filing
Lantheus Holdings filed a proxy statement on August 3, 2026, providing details for shareholder voting and corporate governance matters.
Lantheus to be acquired by Curium for $102.50 per share in cash plus CVRs
Curium and Lantheus (LNTH) announced that Curium US Holdings and Lantheus have entered into a definitive agreement under which Lantheus will merge with a wholly-owned subsidiary of Curium US. Under…
Curium strikes up to $8 bln deal for radiopharma peer Lantheus
Curium has agreed to buy radiopharmaceutical company Lantheus Holdings in a deal worth up to $8 billion, the companies said on Monday.
Curium to acquire Lantheus for up to $114.50 per share
07:34 EDT Curium to acquire Lantheus (LNTH) for up to $114.50 per share
Curium Announces Definitive Agreement to Merge with Lantheus
BOSTON and BEDFORD, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Curium™, a leading, global radiopharmaceutical company with proven expertise in the development, manufacturing and supply of radiopharmaceu...
Lantheus price target raised to $129 from $97 at B. Riley
B. Riley raised the firm’s price target on Lantheus (LNTH) to $129 from $97 and keeps a Buy rating on the shares. Curium is reportedly in advanced talks to acquire…